Pancreatic Cancer Research

ResearcherFujian Medical UniversityActive in the last 2 years

Ning Pu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3123-493X; OpenAlex author ID A5053958827, A5139447310. Sources: OpenAlex.

Their work

Papers
41 (first author 7, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
115
Papers, trials and grants by year

2017: 1 paper · 2018: 3 papers · 2019: 5 papers · 2020: 3 papers · 2021: 5 papers · 2022: 8 papers · 2023: 2 papers · 2024: 1 paper · 2025: 4 papers · 2026: 9 papers

Papers 41

  1. Pathomics Signature for Prognosis and CA19-9 Interception in Pancreatic Ductal Adenocarcinoma: A Real-Life, Multi-Center Study. Last author DOI 10.1002/advs.202515952↗
  2. Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis. Co-author DOI 10.1093/jnci/djag235↗
  3. Supervising the recurrence of pancreatic ductal adenocarcinoma using CtDNA-based MIR129-2 methylation detection. Co-author DOI 10.1097/js9.0000000000003449↗
  4. RASA2 Promotes Pancreatic Cancer Metastasis by Activating TGFβ-Dependent Non-canonical Hedgehog Signaling. Co-author DOI 10.1158/0008-5472.can-26-0333↗
  5. Benefit of Adjuvant Therapy After Neoadjuvant Therapy and Resection for Patients with Pancreatic Cancer: A Systematic Review and Meta-analysis. Co-author DOI 10.1245/s10434-026-19841-5↗
  6. ASO Visual Abstract: Benefit of Adjuvant Therapy after Neoadjuvant Therapy and Resection for Patients with Pancreatic Cancer: A Systematic Review and Meta-anal… Co-author DOI 10.1245/s10434-026-19926-1↗
  7. Gut microbiota and pancreatic cancer: tumorigenesis, progression, and clinical applications. Last author DOI 10.20892/j.issn.2095-3941.2025.0650↗
  8. M1 Macrophage-derived TNF-α Promotes Pancreatic Cancer Ferroptosis via p38 MAPK-ACSL4 Pathway. Co-author DOI 10.2174/0115665240374551250630075409↗
  9. [Repositioning pancreatic surgery and pancreatic surgeons in the era of multidisciplinary treatment for pancreatic cancer]. Co-author DOI 10.3760/cma.j.cn112139-20260316-00108↗
  10. The Crosstalk with CXCL10-Rich Tumor-Associated Mast Cells Fuels Pancreatic Cancer Progression and Immune Escape. Last author DOI 10.1002/advs.202417724↗
  11. The Evolutionary Trajectory and Prognostic Value of GITR+ Tregs Reprogramed by Tumor-Intrinsic PD-1/c-MET Signaling in Pancreatic Cancer. Co-author DOI 10.1002/advs.202500806↗
  12. Intratumoral IL-33 + CD4 + FoxP3 + regulatory T cell infiltration determines poor clinical outcomes and intensive immunoevasive contexture in patients with pan… Co-author DOI 10.1097/js9.0000000000002733↗
  13. Development and Validation of a Cell-Free DNA Fragmentomics-Based Model for Early Detection of Pancreatic Cancer. Co-author DOI 10.1200/jco.24.00287↗
  14. Poor clinical outcomes and immunoevasive contexture in CD161+CD8+ T cells barren human pancreatic cancer. Last author DOI 10.1136/jitc-2023-008694↗
  15. Tumor Microenvironment Responsive CD8+ T Cells and Myeloid-Derived Suppressor Cells to Trigger CD73 Inhibitor AB680-Based Synergistic Therapy for Pancreatic Ca… Co-author DOI 10.1002/advs.202302498↗
  16. Therapeutic advances targeting tumor angiogenesis in pancreatic cancer: Current dilemmas and future directions. First author DOI 10.1016/j.bbcan.2023.188958↗
  17. Association of Matrix Metalloproteinase 7 Expression With Pathologic Response After Neoadjuvant Treatment in Patients With Resected Pancreatic Ductal Adenocarc… Co-author DOI 10.1001/jamasurg.2022.1362↗
  18. Current status and future perspectives of clinical research in pancreatic cancer: Establishment of evidence by science. Co-author DOI 10.1002/jhbp.1045↗
  19. Tumor-associated N1 and N2 neutrophils predict prognosis in patients with resected pancreatic ductal adenocarcinoma: A preliminary study. Last author DOI 10.1002/mco2.183↗
  20. Obstructive sleep apnea predicts pathologic response to neoadjuvant therapy in resected pancreatic ductal adenocarcinoma. First author DOI 10.1002/mco2.184↗
  21. Deep insight into lymph node metastasis in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.ejso.2022.06.027↗
  22. A metabolism-relevant signature as a predictor for prognosis and therapeutic response in pancreatic cancer. First author DOI 10.1177/15353702211049220↗
  23. Comprehensive Analysis of Somatic Mutations in Driver Genes of Resected Pancreatic Ductal Adenocarcinoma Reveals KRAS G12D and Mutant TP53 Combination as an In… Co-author DOI 10.1245/s10434-021-11081-z↗
  24. Commentary on "Nationwide Validation of the 8th American Joint Committee on Cancer TNM Staging System and Five Proposed Modifications for Resected Pancreatic C… Co-author DOI 10.1245/s10434-022-12148-1↗
  25. Lymph Node Metastatic Patterns and Survival Predictors Based on Tumor Size in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1007/s12325-021-01819-2↗
  26. An iodine-125 seed strand combined with a metal stent versus a metal stent alone for obstructive jaundice caused by pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.brachy.2020.10.004↗
  27. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic c… First author DOI 10.1038/s41419-021-04293-4↗
  28. Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003570↗
  29. Improved Assessment of Response Status in Patients with Pancreatic Cancer Treated with Neoadjuvant Therapy using Somatic Mutations and Liquid Biopsy Analysis. First author DOI 10.1158/1078-0432.ccr-20-1746↗
  30. Association of Germline Variants in Human DNA Damage Repair Genes and Response to Adjuvant Chemotherapy in Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.jamcollsurg.2020.06.019↗
  31. CD73 acts as a prognostic biomarker and promotes progression and immune escape in pancreatic cancer. First author DOI 10.1111/jcmm.15500↗
  32. Radiofrequency ablation in combination with an mTOR inhibitor restrains pancreatic cancer growth induced by intrinsic HSP70. First author DOI 10.1177/1758835920953728↗
  33. TRAF6 regulates YAP signaling by promoting the ubiquitination and degradation of MST1 in pancreatic cancer. Co-author DOI 10.1007/s10238-018-00543-6↗
  34. Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway. Co-author DOI 10.1016/j.canlet.2019.06.013↗
  35. Genetic landscape of prognostic value in pancreatic ductal adenocarcinoma microenvironment. Co-author DOI 10.21037/atm.2019.10.91↗
  36. Optimized modification of the eighth edition of AJCC TNM staging system for resected pancreatic ductal adenocarcinoma. Co-author DOI 10.2217/fon-2019-0264↗
  37. Independent effect of postoperative neutrophil-to-lymphocyte ratio on the survival of pancreatic ductal adenocarcinoma with open distal pancreatosplenectomy an… Co-author DOI 10.7150/jca.35856↗
  38. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer. Co-author DOI 10.1186/s12967-018-1673-6↗
  39. Survival prediction in pancreatic cancer patients with no distant metastasis: a large-scale population-based estimate. Co-author DOI 10.2217/fon-2017-0380↗
  40. Neutralizing TGF-β promotes anti-tumor immunity of dendritic cells against pancreatic cancer by regulating T lymphocytes. Co-author DOI 10.5114/ceji.2018.77381↗
  41. Alkaline Phosphatase-To-Albumin Ratio as a Prognostic Indicator in Pancreatic Ductal Adenocarcinoma after Curative Resection. Co-author DOI 10.7150/jca.20917↗

Closest collaborators

The 25 strongest of 115 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hanlin Yin · 21 shared papers, 2018–2026 · strength 3.58
  2. Wenchuan Wu · 22 shared papers, 2017–2026 · strength 3.22
  3. Qiangda Chen · 16 shared papers, 2019–2026 · strength 2.64
  4. Wenhui Lou · 15 shared papers, 2018–2026 · strength 2.46
  5. Jun Yu · 16 shared papers, 2019–2026 · strength 2.33
  6. Taochen He · 8 shared papers, 2024–2026 · strength 1.73
  7. Wenhui Lou · 9 shared papers, 2017–2022 · strength 1.11
  8. Shanshan Gao · 10 shared papers, 2017–2025 · strength 1.06
  9. Joseph R. Habib · 7 shared papers, 2019–2025 · strength 1.01
  10. Jin Peng He · 6 shared papers, 2020–2026 · strength 0.85
  11. Liang Liu · 4 shared papers, 2023–2026 · strength 0.85
  12. Wenquan Wang · 4 shared papers, 2023–2026 · strength 0.85
  13. Yun Jin · 4 shared papers, 2025–2026 · strength 0.83
  14. Zhihang Xu · 4 shared papers, 2025–2026 · strength 0.82
  15. Sami Shoucair · 5 shared papers, 2022–2025 · strength 0.78
  16. José Oberholzer · 3 shared papers, 2026 · strength 0.69
  17. Dilmurodjon Eshmuminov · 3 shared papers, 2026 · strength 0.69
  18. Víctor López‐López · 3 shared papers, 2026 · strength 0.69
  19. Michael C. Frey · 3 shared papers, 2026 · strength 0.69
  20. So Heun Lee · 3 shared papers, 2026 · strength 0.69
  21. Ralph Fritsch · 3 shared papers, 2026 · strength 0.69
  22. Changhoon Yoo · 3 shared papers, 2026 · strength 0.69
  23. Yanfei An · 3 shared papers, 2023–2026 · strength 0.66
  24. L Liu · 1 shared paper, 2026 · strength 0.63
  25. Dansong Wang · 7 shared papers, 2017–2021 · strength 0.60

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.